DBVT News and Press, DBV Technologies S.A. From 08/20/21

GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections an...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN ...

DBV Technologies S.A. (DBVT) Q2 2021 Earnings Conference Call August 02, 2021 05:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Conference Call Participants Graig Suvannavej...

DBV Technologies (NASDAQ:DBVT): Q2 GAAP EPS of -$0.56 beats by $0.01. Cash and Cash Equivalents as of June 30, 2021 were $125.5 million, compared to $196.4 million as of December 31, 2020 and $152.5 million as of March 31, 2021. Press Release For further details see: DBV Technologies EP...

Montrouge, France, August 2, 2021 DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments Business Highlights : Viaskin Peanut US: DBV submitted the protocol for the 6-month adhesion and safety stu...

Montrouge, France, July 26, 2021 DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compan...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

Montrouge, France, June 2, 2021 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé...